Nymox Pharmaceutical Corp (NASDAQ:NYMX)

zzlangerhans (99.23) Submitted: 5/13/2011 1:14:22 AM : Start Price: $7.78 NYMX Score: -8.44

I've had a strong dislike and distrust of this company going back four years to when I first started to follow them. Back then they used to talk about Alzheimer's disease and their theory that senile plaques were caused by bursting balls of protein, or spherons. We haven't heard much about spherons since then though. The company also wastes time and money to market some very dubious products such as a purported urine test for Alzheimer's and a urine drug test for nicotine (yeah, seriously) that generate pathetic amounts of revenue. Product sales were only 0.6M for all of 2010.

The real story for Nymox now is NX-1207, their developmental compound for BPH. No one outside of Nymox knows what NX-1207 is, since the company has refused to provide basic information regarding its composition and mechanism. Other developmental biotechs don't have a problem sharing that information about their pipeline candidates, so I have to wonder if Nymox is afraid of scientific scrutiny. Most of Nymox stock's recent strength derives from last December's deal with Recordati for European rights to NX-1207. The royalties were juicy at 26-40% but the upfront payment was only 13M, pocket change for a large pharmaceutical distributor.

NX-1207 is currently in a phase III trial for BPH but no one knows how far Nymox has progressed with enrollment, or when topline data can be expected, because the company has refused to divulge this information. Again, most other similar companies keep their investors updated on these material developments. Management seems to have arbitrarily selected a one year efficacy data point for the phase III trial, although their phase II studies were only designed to demonstrate efficacy after three months as a primary endpoint. Confidence? Or stupidity? Check out their 1995 level company website and decide for yourself.

If we do get any heads up regarding the timing of topline data of the phase III trials, Nymox is a prime candidate for put options (although there does not seem to be an options market in Nymox at the present time).

pcolajoe (83.91) Submitted: 8/16/2010 11:55:57 AM : Start Price: $4.41 NYMX Score: +66.67

Steady growth.

mshakin1 (< 20) Submitted: 5/27/2010 2:50:11 PM : Start Price: $4.71 NYMX Score: +56.20

The NYMOX drug for BPH, NX1207, is head and shoulders above all the existing drugs for this ailment, which affects tens of millions of middle age and elderly men. Not only is NX1207 so much more effective than Flomax and Avodart is decreasing BPH, but it also doesn't have the sexual side effects. And instead of taking hose drugs every day forever, NX1207 is an injection administered in a urologist's office only once every several years.
This drug has tremendous potential. To become a blockbuster, it doesn't have to be recognized as a great drug by consumers, but rather by urologists, who will be well aware of how much better it is than the alternative oral drugs.

shupenobama (31.55) Submitted: 11/27/2009 7:54:04 PM : Start Price: $4.30 NYMX Score: +72.69

will explode when BPH treatment nears approval

mepedrou (< 20) Submitted: 1/8/2009 2:28:58 PM : Start Price: $3.55 NYMX Score: +85.13

nx 1207 drug a guaranteed winner

GershwinStephen (< 20) Submitted: 1/30/2008 5:33:55 PM : Start Price: $5.07 NYMX Score: +60.77

acquisiton,

NeroSagetrade (93.92) Submitted: 10/11/2007 6:53:50 PM : Start Price: $6.25 NYMX Score: -43.86

There are far too many of these types of pharmaceutical companies out there...plenty of promise, huge valuation and failure to deliver. Nymox currently has one...yes..only one drug currently in late stage trials to treat enlarging prostates. The company has managed just 450k in sales for the entire year yet is valued at over 183 million dollars. Losses are increasing, and based on my estimates, they dont even have enough cash to get out of Q1 2008! Over 400 times price to sales, 58 times book, and increasing losses..where's the buy button?!! If you look historically at the long-term chart, this falls mercilessly for 2-3 months after every large rise.

Nero

Sagetrade

Voyt608 (< 20) Submitted: 4/12/2007 9:07:23 AM : Start Price: $5.61 NYMX Score: +50.93

Non estrogenic treatment for benign proatatic hyperplasia with proven efficacy ih reducing symptoms such as frepuent voiding, urgency, nocturia, dripping etc. No significant side effects and a 30% reduction in prostate size in late trials. Tremendous market potential.

NetscribeHealthC (< 20) Submitted: 3/23/2007 9:26:46 AM : Start Price: $5.95 NYMX Score: -42.02

Nymox Pharmaceutical Corporation (Nymox) is a biopharmaceutical company that owns and operates business through two subsidiaries: Nymox Corporation, a wholly owned subsidiary and Serex, Inc., a majority owned subsidiary. The company has three products in its portfolio; AlzheimAlert meant to measure the level of a brain protein, NicAlert to determine smoking status and TobacAlert determination of a person’s level of exposure to tobacco products including second hand smoke.

The company is pursuing research and development pipeline of drug and diagnostic products in development for the treatment of such conditions and diseases as enlarged prostate (benign prostatic hyperplasia (BPH)), Alzheimer's disease (AD), E. coli O157:H7 contamination of food and drink products, and bacterial infections and for the diagnosis of AD and other indications.

Nymox’s financial statements indicate that it is still very much in its development phase. For the fiscal 2006 its revenues were mere $0.44 million whereas it reported net loss of $4.89 million which was 63% more than the previous year.

The driver for this stock would be its Phase II product candidate NX-1207 which is meant to treat BPH. The stocked reacted positively on the recent announcement of positive test data.

The company’s valuation looks expensive especially if one takes into account its $ 44 million deficit and that it is going to take few years for it to generate positive free cash flows. Thus in today’s environment where risk aversion is the norm this stock doesn’t make the grade. Hence its better to be prudent while thinking of investing in the stock.

fiona53 (< 20) Submitted: 2/18/2007 4:03:24 AM : Start Price: $5.70 NYMX Score: +49.41

very interesting pipeline

bdylan (< 20) Submitted: 2/8/2007 9:26:10 PM : Start Price: $5.25 NYMX Score: +61.76

Nymox has intellectual patented technology worldwide with statin gene marker for alzheimers disease.
Their drug for shrinking prostate gland that has enlarged has no known high risk side effects. Their research on eliminating the ecoli bacteria in food is moving forward . I bleive this company is positioned for solid growth thru revenues and earnings generated by these proprietory techniques and the royalties generated by these products :leased: to other major pharmaceutical companies should enhance earnings and price..